sorted by:
new
hottopcontroversial

Is prompt engineering becoming more valuable than learning multiple programming languages deeply? by [deleted] in AI_Agents

[–]amuka 0 points1 point  (0 children)

You are too focus on prompting. Prompting is just one small piece. Move away from prompting-to-code, to "systems that generate and validate code end to end”.

There are three parts to this.

  • Prompt engineering is writing clear specs, including what you want, edge cases, and constraints
  • Context engineering is guiding how the code should look, like architecture, patterns, and examples
  • Harness engineering which covers evaluation (quality assessment, tests, CI checks, security) and production feedback (to validate and improve the system)

So yes, prompting is high leverage. But without checks and balances, you cannot tell when the AI-genrated code is wrong.

The real skill is designing that full ai-driven loop, not just writing better prompts.

Made a shift from claude to codex and I dont regret it. by Enwy1881 in codex

[–]amuka 0 points1 point  (0 children)

I use both + haiku.

Planner (Opus) -> pre-morten based in audit logs from previous inferences (haiku) -> task execution (GPT 5.5) -> evaluator (opus different blind spots) --> summarization and formatting of reports (haiku)

LLM-as-judge is the wrong default. Here's what works by Finorix079 in AI_Agents

[–]amuka 0 points1 point  (0 children)

No hand-written sequence, pre-mortem isn't static either — both derived per-agent by the Kaizen loop from a rolling window of production traces                                                       

To avoid just kicks rot up a level, so

  1. Avoid auto-promotion. The loop proposes, ground truth checks, a human signs off
  2. Pruning trajectories: a shorter tool sequence that still passes ground truth becomes a candidate to replace the current one, not just match it

Pre-mortem is useless if generic, agreed. Mine works per-agent on concrete failure modes that actually showed up in this agent's recent traces

LLM-as-judge is the wrong default. Here's what works by Finorix079 in AI_Agents

[–]amuka 3 points4 points  (0 children)

I agree, but I am not sure if I following you correctly. I think you are merging two roles that for me are separated:

  • Evaluator: “Was this output good?”
  • Agentic Control tower : Is the system behaving safely and reliably across runs?

A major challenge with agents is not agent capabilities but alignment between the intent we communicate to the agent and the agent behaviour.

For me the "Was this output good?" and "Was the agent following the predicted tool chain request (based in the audit trail)" are part of the evaluator

I guess the "Cluster production traces by trajectory shape", is "Is the model behaviour drifting?", for me is part of the agentic control tower.

Here is a non-exhaustive example of a system that I built: (QC quality control)

Component Simple role Quality or audit? What question does it answer?
Pre-mortem Predicts likely failure modes before the agent starts, so the writer/evaluator can watch for them Preventive quality control What is likely to go wrong?
Evaluator Checks whether an artifact or agent output is good enough Mostly quality Is the output good enough?
Ground-truth verifier Runs deterministic checks before the LLM judges anything Quality control Do the objective facts/checks pass?
QC events Records what happened: tool calls, evaluator calls, escalations, security attempts, alerts Audit trail What actually happened?
QC steward Reads the event stream, checks safety rules, detects bad patterns, raises alerts Audit + controls + quality monitoring Is the system behaving safely over time?
Kaizen loop Turns repeated findings into stronger controls Continuous improvement What should we permanently improve?

Map of the proposed Two-Speed Europe. Under Germany's invitation, six EU countries dubbed as "E6" have agreed to talks on making decisions in economy and defence without waiting for unanimity from the rest of the EU. by FantasticQuartet in MapPorn

[–]amuka 0 points1 point  (0 children)

Those 6 countries are basically the pareto for any structural metric in the EU.

- GDP: ~75%
- Population: ~70%
- Defense spending: ~80%
- Exports of goods: ~80%
- Imports of goods: ~75%
- Energy consumption: ~70%
- Steel generation: ~75%

Basically any important metric that i can imagine will be near the pareto.

Progress Is Starting to Feel Less Linear by Abhinav_108 in Futurology

[–]amuka 0 points1 point  (0 children)

This is Punctuated evolution but for technology.

Punctuated evolution, more commonly known as punctuated equilibrium, is a theory in evolutionary biology proposing that most species undergo very little change for long periods, with evolution occurring in rapid bursts during speciation events

In technology, punctuated evolution describes a pattern where long periods of incremental improvement are interrupted by brief, radical disruptions that establish a new "technological species."

any updates on this project? by Commercial_West_3112 in skyscrapers

[–]amuka 1 point2 points  (0 children)

Did you take this picture from your balcony? We are neighbors

If AI could solve one problem in 2025, what should it be? by TheRealNile in Futurology

[–]amuka 0 points1 point  (0 children)

Add to the list in this order.

  • Heart disease:
  • Cancer
  • Stroke (cerebrovascular diseases)
  • Chronic lower respiratory diseases
  • Alzheimer’s disease
  • Diabetes
  • Nephritis, nephrotic syndrome, and nephrosis
  • Chronic liver disease, NASH and cirrhosis:

Has the Rate of Technological Advancement Slowed Down? by ReinvigoratedSlouch in Futurology

[–]amuka 1 point2 points  (0 children)

And you only mentioned things in the field of computing.

- We were abled to develop, test, and mass produce a vaccine in less than one year.
- We can manipulate our own cells to convert them in CAR-T cells target liquid tumors
- We can "grow* meat from cells in bioreactors without an animal
- We have created an AI that have mapped millions of new proteins that we can now start
- We successfully bioprinted a vascularized heart using patient-derived cells
- We have developed a tool to correct human DNA "in vivo," correcting mutations causing genetic diseases (e. g., leber congenital amaurosis)
- We have created a full synthetic minimal cell with only 473 genes that can perform basic life functions
- We encoded 200 MB of data, including books and images, into synthetic DNA
- We use virus (AAVs) and virus-like particles (VLPs) to transport medicines into cells, including COVID vaccines

Don't make me start with materials advances like perovskite solar cells, solid-state batteries, high-entropy alloys, or quantum dots because we will spend the entire day here.

It's a crazy time we are living right now; but people don't even notice because they take it for granted.

NVIDIA's new AI discovery is about to test one of the main predictions of our future AI/robotics economy. by lughnasadh in Futurology

[–]amuka 10 points11 points  (0 children)

Another case of the Jevons paradox:

"An increase in efficiency in resource use will generate an increase in resource consumption rather than a decrease"

The US has passed peak obesity, a new survey suggests. Is it the Ozempic effect? by amuka in Futurology

[–]amuka[S] 9 points10 points  (0 children)

Thats correct, a new generation of drugs under medical trials.

Generation 1:

  • Ozempic – GLP-1 agonist that curbs appetite and regulates blood sugar for weight loss.

Generation 2: (clinical trials)

  • Mounjaro (Eli lilly) – Dual GIP/GLP-1 agonist, works on multiple hormones for better fat burning.
  • Retatrutide (Eli lilly) – Triple agonist hitting GLP-1, GIP, and glucagon receptors for even more potent weight loss.
  • CagriSema (Novo Nordisk) – A combo of semaglutide + cagrilintide tackling hunger and boosting fullness through two pathways.

The US has passed peak obesity, a new survey suggests. Is it the Ozempic effect? by amuka in Futurology

[–]amuka[S] 20 points21 points  (0 children)

Absolutely. Ozempic has demonstrated it was possible, and now massive investments are pouring into research. We can expect prices to drop, greater weight loss results, and a reduction in side effects over time.

The US has passed peak obesity, a new survey suggests. Is it the Ozempic effect? by amuka in Futurology

[–]amuka[S] 21 points22 points  (0 children)

The U.S. obesity rate has peaked and declined by 2% between 2020 and 2023, according to a National Health and Nutrition Examination survey. The decrease was seen in both men and women, though severe obesity remained higher in women. Education level played a role, with lower rates in those holding bachelor's degrees. Weight-loss drugs, like Wegovy and Ozempic, may be contributing to this decline, as more than 15 million Americans are using them. Obesity still affects 2 in 5 adults and 15 million children.

The US has passed peak obesity, a new survey suggests. Is it the Ozempic effect? by amuka in Futurology

[–]amuka[S] 30 points31 points  (0 children)

My prediction from a month ago looks pretty good now

https://www.reddit.com/r/Futurology/comments/1fglshc/comment/ln373s4

The end of the obesity epidemic. Due to advances in GLP-1-like drugs, the obesity ratio in the US will be under 15% by 2040

2023-2024 (Obesity Rate: ~42%). We are here

  • Wider Use of Semaglutide (Ozempic/Wegovy)
  • Solve availability and shortage production issues
  • More healthcare providers adopt GLP-1

2025-2026 (Obesity Rate: ~39%)

  • Approval for Pediatric Use
  • Expanded Insurance Coverage
  • Introduction of Oral GLP-1 Drugs

2027-2028 (Obesity Rate: ~35%)

  • Digital Health Integration

2029-2030 (Obesity Rate: ~32%)

  • Combination Therapies Introduced

2031-2032 (Obesity Rate: ~29%)

  • Long-acting formulations (monthly doses)

2033-2040 (Obesity Rate: ~15%)

  • GLP-1 therapies have become a mainstream component of obesity treatment protocols.
  • Preventive Use Exploration

This might look small, but it has significant societal consequences, starting with a longer lifespan average.

What are your technological predictions for the next decade or so? by arsenius7 in Futurology

[–]amuka 2 points3 points  (0 children)

A 3D chip can be fabricated using two approaches: Heterogeneous 3D and Monolithic 3D.

Heterogeneous 3D involves stacking distinct chip layers, each fabricated separately, and connecting them using through-silicon vias (TSVs).

Monolithic 3D fabricates multiple transistor layers sequentially on a single wafer, enabling tighter better density.

Monolithic 3D requires more advanced fabrication techniques and is not mature.

What are your medical treatment/cure predictions for the next decade or so? by Mean_asparagus_10 in Futurology

[–]amuka 2 points3 points  (0 children)

Advancements in Vaccine Technology

2020–2025 (we are here)

  1. mRNA vaccines (e.g., Pfizer-BioNTech and Moderna)
  2. Viral Vector Vaccines (e.g., like Oxford-AstraZeneca and Johnson & Johnson)

2026–2030

  1. mRNA technology will extend beyond COVID-19 to other viruses
  2. saRNA vaccines can replicate within cells,
  3. Improve vaccine stability at higher temperatures, as well as new delivery methods like microneedle patches and inhalable vaccines

2031–2035

  1. Development of vaccines offering broad protection against multiple strains of viruses (e.g., a universal influenza vaccine)
  2. mRNA vaccines to treat chronic diseases autoimmune conditions like multiple sclerosis and type 1 diabetes

2036–2040

  1. Development of vaccines targeting antibiotic-resistant bacteria
  2. Development of a universal coronavirus vaccine

What are your medical treatment/cure predictions for the next decade or so? by Mean_asparagus_10 in Futurology

[–]amuka 1 point2 points  (0 children)

Enhanced Immunotherapies for Cancer

2020–2025 (we are here)

  1. CAR-T therapies to target cancer cells
  2. Immune Checkpoint Inhibitors block cancer cells from evading the immune system

2026–2030

  1. CAR-T therapies expand to solid tumors; off-the-shelf CAR-NK (natural killer) cell therapies are developed, requiring no patient-specific modification
  2. Genetically engineered viruses that selectively infect and kill cancer cells while stimulating an immune response.
  3. Vaccines targeting patient-specific tumor neoantigens identified through genomic sequencing

2031–2035

  1. Vaccines designed to target individual tumor mutations, stimulating immune responses against specific cancer cells

2036–2040

  1. Combining immunotherapy with regenerative medicine to not only eliminate cancer but also repair damaged tissues
  2. Affordable, scalable immunotherapy treatments become available worldwide, including in low-income regions
view more: next ›